Although cancer is a disease that will afflict one out of three people in the Western world, when considered at a cellular level, it is a rare clonal event. Long-lived organisms, such as humans, have evolved strategies to restrict the development of potentially malignant cells, and one such mechanism is the coupling of proliferative and apoptotic pathways. Multiple oncogenes have the ability to trigger apoptosis when expressed in an inappropriate fashion, and this is thought to restrict tumour formation by eliminating potentially malignant cells that have acquired a mutation stimulating proliferation. Hence for a tumour to arise, in addition to mutations that drive proliferation, mutations that prevent apoptosis are also a prerequisite.
Introduction
Cancer is a disease that is caused by the acquisition of mutations that can modulate the control of growth and survival, and these genetic events affect the expression or function of genes that are broadly classified into two groups, oncogenes and tumour supppressors. Proto-oncogenes are cellular genes involved in the control of growth and survival under normal physiological conditions, whose activation or over-expression as a consequence of mutation (rendering them oncogenes) can positively contribute to tumour formation. In contrast, tumour suppressors act in normal cells as negative controllers of cell growth and survival, or are involved in the maintenance of genomic integrity and are deleted or are inactive in tumour cells. Consequently, activation of an oncogene is a dominant genetic event, whereas inactivation of a tumoursuppressor gene is normally recessive.
Since cancer is a disease characterized by excessive proliferation, it is not surprising that many oncogenes encode proteins that promote proliferation. The role of proto-oncogenes in regulating normal proliferation has been established since the 1970s, when the first oncogenes were cloned. In contrast, the ability of oncogenes to induce programmed cell death, or apoptosis, was not recognized until the early 1990s. Pioneering work with the c-myc oncogene demonstrated that it is also capable of stimulating apoptosis [1] . Expression of the transcription factor c-Myc occurs in normally cycling cells and when ectopically expressed in a quiescent cell is sufficient to drive the cells into Sphase. While activating a proliferative programme, c-Myc also stimulates apoptosis; however, other signals from the external environment that promote survival can suppress this apoptotic programme. Many soluble growth factors can function as survival factors, and are capable of blocking apoptosis in response to c-Myc expression. Under normal physiological conditions, entry of a cell into the cell cycle and the concomitant activation of c-Myc would occur in the presence of these survival signals, preventing c-Myc-induced apoptosis. This proto-oncogene is activated in a number of tumours by overexpression as a consequence of gene amplification or translocation. The outcome of this oncogenic activation of c-Myc, proliferation or apoptosis, is dependent on the presence or absence of survival signals provided by the surrounding environment [2] (Figure 1 ).
The ability to induce apoptosis has been extended to many other growthpromoting oncogenes using both in vitro and in vivo systems. One example is E2F1, a member of a family of transcription factors (E2F1-6) that are critical regulators of the cell cycle, mediating expression of a number of genes whose products play regulatory roles in the cell cycle, including the cell-cycle-regulated kinase cdc2, cyclin E and those with a functional role in DNA synthesis itself, such as DNA polymerase ␣ and dihydrofolate reductase [3] . E2F activity is tightly regulated and an important mechanism of control is through interaction with members of the product of the pRB (retinoblastoma susceptibility locus) family. E2F and pRB form a repressive complex that inhibits transcription; however, in response to growth factor signalling, pRB is hyperphosphorylated as cells pass through G 1 and is unable to interact with E2F, enabling these transcription factors to activate expression of genes necessary for DNA synthesis [3] . The important role of this family of transcription factors as regulators of proliferation is reflected in the fact that deregulation of E2F activity is a common event in human cancer and can occur by a number of distinct mechanisms including loss of the tumour suppressor pRB [3] .
In addition to regulating genes necessary for the cell cycle, forced expression of E2F1 in quiescent cells is sufficient to induce entry into DNA synthesis; however, this is an abortive DNA synthesis, since the cells undergo apoptosis. The ability of E2F1 to induce apoptosis has also been demonstrated in vivo in a number of studies. Mice null for pRB fail to develop in part as a result of apoptosis in a number of tissues, illustrating that loss of the normal regulation of E2F is sufficient to trigger apoptosis in vivo. Although loss of pRB has consequences in the addition to the deregulation of E2F1 activity, the role of E2F1 in mediating this apoptosis is illustrated in mouse embryos null for both pRB and E2F1, which display much reduced apoptosis, although the embryos still die before birth [4] . A role for E2F1 as a mediator of apoptosis is supported by the analysis of the phenotype of E2F1-null mice; these mice develop normally, but are tumour-prone, exhibiting a reduction in apoptosis in certain tissues [5] . Oncogenes stimulate proliferation and apoptosis Activation of the proto-oncogene c-myc occurs in response to growth factor signalling, stimulating both proliferation and apoptosis. In addition to stimulating c-Myc, growth factors can concomitantly activate survival signalling that blocks the apoptosis stimulated by c-Myc, allowing the cell to proliferate. If c-Myc is activated by an oncogenic event, whether the outcome of this event is proliferation or apoptosis will be determined by the extent of survival signals that the cell receives.
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Why do oncogenes stimulate apoptosis? It seems paradoxical that the genes that promote cancer can induce apoptosis. It should be noted that cancer does not arise as a consequence of a single genetic change, rather it requires a number of independent genetic events. In the absence of a compensating mutation blocking apoptosis, activation of a single oncogene may lead to the elimination of the cell by apoptosis, rather than unrestrained proliferation. Thus oncogene-induced apoptosis is a mechanism of tumour suppression, eliminating cells with potentially malignant genetic changes, thus protecting the organism from the development of cancer.
The importance of escape from apoptosis in the development of a tumour was first suggested by the identification and characterization of B-cell lymphoma 2 gene (bcl-2). Follicular lymphoma is associated with a reciprocal translocation, which brings the chromosome 18 gene, bcl-2, under the regulation of an immunoglobulin locus, deregulating its expression. In these tumours, over-expression of Bcl-2 blocks the normal apoptosis of B-cells, contributing to tumorigenesis by promotion of survival rather than by enhancing proliferation. Bcl-2 is an important regulator of apoptosis, being capable of blocking cell death in response to multiple apoptosis-promoting agents by blocking the activation of caspases, critical proteases that mediate apoptosis [6] . Transgenic studies have demonstrated that the activation of proliferative oncogenes, such as c-Myc, can co-operate with Bcl-2 in tumour formation, underlining the role of apoptosis in restricting tumour development [6] .
p53 is a mediator of oncogene-induced apoptosis
What is the molecular mechanism of oncogene-induced apoptosis? There seem to be multiple downstream mediators of this property of oncogenes with a role for both death receptors and mitochondrial apoptotic pathways described. One important mediator of oncogene-induced apoptosis that has received much attention is p53, a critical regulator of apoptosis, and the most commonly mutated gene in human cancer [7] .
The transcription factor p53 is activated in response to multiple stresses that may be associated with the initiation or development of cancer, including DNA damage, hypoxia and telomere erosion [2] . This transcription factor can activate mutiple genes that mediate a number of biological programmes, including apoptosis, growth arrest, differentiation and senescence, as well as DNA repair, all of which may contribute to its ability to function as a tumour suppressor.
The DNA tumour viruses, including adenovirus, SV40 (simian virus 40) and human papillomavirus, provide an excellent illustration of the role of p53 in triggering oncogene-induced apoptosis. These small viruses depend on host factors for their replication and so express viral proteins that interfere with the pRB protein family, deregulating E2F activity. This ensures expression of the cellular replicative machinery, but carries with it the drawback of activation of the E2F apoptotic signal. Consequently, each of these distinct viruses encode proteins with the ability to inhibit p53 activity [8] . SV40 large T-antigen and adenovirus E1B 55K bind and inactivate p53, whereas the high-risk human papillomavirus encodes a protein, E6, that binds and mediates the degradation of p53, hence cells expressing these viral oncoproteins are functionally null for p53 ( Figure 2) . Expression of the viral proteins that deregulate E2F activity in the absence of those that inhibit p53 function converts the outcome from proliferation into apoptosis.
A role for p53 in apoptosis triggered by deregulation of E2F is also supported by a number of in vivo studies, including analysis of pRB-null embryos, where loss of p53 function blocks apoptosis in a number of tissues [9] . A role for p53 in oncogene-induced apoptosis is not restricted to the The DNA tumour viruses, adenovirus, SV40 and human papillomaviruses (HPV) all encode proteins that inhibit the function of pRB family members thus generating a proliferative signal. Since this also induces an apoptotic response, each of these viruses expresses a protein that inhibits p53 function thus blocking apoptosis. SV40 large T-antigen (LT) and adenovirus E1B 55K bind and inhibit p53 activity. The high-risk HPVs encode a protein, E6, that mediates the ubiquitindependent degradation of p53. Thus infection of a cell with any of these viruses renders it functionally null for p53. deregulation of E2F, rather seems to be a common feature of the proliferationpromoting oncogenes, including c-Myc [2] .
ARF stabilizes p53 in response to oncogenic signalling
Oncogenic signalling by over-expression of oncogenes including c-Myc and E2F1 can stabilize p53 [2] . p53 induces transcription of mdm2, a gene encoding a ubiqutin ligase that interacts with p53 triggering its ubiqutindependent degradation. Hence, under normal conditions p53 is maintained at low levels by this negative-feedback loop; however, in response to stresses that activate p53, such as DNA damage or hypoxia, this feedback loop is broken allowing p53 levels to accumulate ( Figure 3 ). One mechanism to interrupt this feedback loop is via induction of the ARF (alternative reading frame) of the INK4a locus (p19 ARF in mouse, p14 ARF in humans). This locus remarkably encodes two loci, both of which can function as tumour suppressors, but since they are read in different reading frames, they share no amino acid homology [10] . ARF can stabilize p53 by binding Mdm2 and preventing the degradation of p53. Oncogenes such as Myc, E1a Ras and E2F1 have all been demonstrated to induce expression of this gene, Figure 3 . ARF stabilizes p53 by preventing its Mdm2-mediated degradation Under normal conditions, p53 levels are maintained by a negative-feedback loop; p53 induces the expression of mdm2. The product of this gene, Mdm2, binds and mediates the ubiquitin-dependent degradation of p53. Oncogenes can stabilize p53 by expression of ARF, which binds Mdm2, thus preventing the degradation of p53.
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In the presence of ARF, Mdm2-mediated degradation of p53 is blocked Mdm2 ARF leading to stabilization of p53. The mechanism of how diverse oncogenes trigger expression of this gene is unclear; however, evidence suggests that p14 ARF may be a direct E2F1 target gene [11] . Almost all tumours contain lesions that lead to deregulation of E2F activity and/or activation of other oncogenes, which would induce ARF, leading to elevated levels of p53. Hence, for a tumour to arise, we would predict that this activation of p53 would have to be abrogated. Whereas loss of p53 would obviously disrupt this pathway, loss of ARF could potentially substitute, and there are experimental data indicating that this can happen. Mice null for ARF develop tumours, indicating that this gene can function as a tumour-suppressor gene, and many tumours that retain wild-type p53 show defects in ARF expression, suggesting that loss of the ability to induce p53 in response to oncogenes allows survival and progression of the tumour cell [12] . This is supported by in vivo models using transgenic mice with c-Myc expression targeted to B-cells, where ARF loss could substitute for loss of p53 in the generation of aggressive lymphomas. However, many of the tumours arising in these mice also acquired p53 mutation at a later stage, indicating that there was still selective pressure to lose p53 in the absence of ARF [13] .
It is of interest to note that ARF does not appear to be induced upon DNA damage, and loss of ARF does not prevent activation of p53 in response to genotoxic stress, although ARF may contribute to the maintenance of this response. Since certain tumours can tolerate p53 in the absence of ARF, responding to oncogenic signalling may be the critical tumour-suppressing function of p53 in many cell types, rather than the ability to respond to other stresses such as DNA damage [10] .
ARF-independent stabilization of p53
While it is clear that ARF can play a role in the stabilization of p53 in response to oncogene expression, emerging evidence indicates that ARF may have p53-independent functions, and additional mechanisms are employed by oncogenes to stabilize p53. As already described, the pRB-null embryo is characterized by apoptosis that is, in part, dependent on p53. In these tissues the elevation of p53 is associated with increased levels of ARF. Surprisingly, in an ARF-null background, the stabilization of p53 is unaffected, indicting that ARF is dispensable for the p53 stabilization seen in response to deregulation of E2F activity [4] . This result is mirrored by other transgenic studies. Targeting of E2F1 expression to the skin leads to induction of ARF, elevation of p53 and apoptosis. In the absence of ARF, the stabilization of p53 is unaffected and the apoptosis is actually increased. In contrast, in the same tissue, c-Myc expression led to the stablization of p53 in an ARF-dependent manner [14] . A similar effect was seen when E2F was deregulated in the brain, with a lack of ARF dependence for the stabilization of p53, despite induction of ARF expression [15] .
What underlies these results? It seems clear that, under some circumstances, ARF can promote the stabilization of p53 in response oncogenes, but at least for E2F other mechanisms must exist. It is of interest that ARF has been reported to have p53-independent properties, including the ability to inhibit the cell cycle via a direct interaction with E2F. The extent to which the p53-independent effects of ARF influence its role as a tumour suppressor remains to be determined, but interestingly, triple-knockout mice, null for ARF, p53 and Mdm2, display a greater frequency of tumours than either p53-or p53/mdm2-null mice [16] . While the precise role of ARF in stabilizing p53 in response to oncogene expression is unclear, stabilization of p53 is a critical event in mediating apoptosis regardless of the mechanism of induction.
p53-independent apoptosis
Although p53 is an important mediator of oncogene-induced apoptosis, oncogenes can trigger apoptosis independently of p53. There are now many reports of oncogenes triggering apoptosis in cells null for p53, firmly demonstrating that p53 is not essential for oncogenes to trigger apoptosis. Furthermore, animal models have demonstrated that, in vivo, a requirement for p53 to mediate oncogene-induced apoptosis is tissue-specific. In mice null for pRB, although the apoptosis in the central nervous system is p53-dependent, loss of p53 has no impact on the apoptosis in the peripheral nervous system [9] .
In addition, although p53 may be essential for apoptosis in certain cell types, even in these cells it is not sufficient. In mouse embryo fibroblasts (MEFs), expression of oncogenes results in stabilization of p53 and apoptosis, whereas, in contrast, expression of p53 alone triggers only a growth arrest [17] . The molecular determinants of whether the outcome of p53 induction is apoptosis or growth arrest are not fully understood. However, recent work has demonstrated that the level of c-Myc can influence the outcome of p53 induction, converting a cell's response from growth arrest to apoptosis. p53 mediates growth arrest by the induction of the cyclin-dependent kinase inhibitor p21, which inhibits the cell cycle, and in certain contexts, expression of this gene can block apoptosis. Myc is recruited to the p21 promoter by the DNAbinding protein Miz and inhibits p53-mediated transcriptional activation of this target gene. In contrast, expression of Myc does not inhibit activation of p53 genes involved in the induction of apoptosis, and in colon cancer cells, this switches the response to p53 expression from growth arrest to apoptosis [18] .
Since oncogenes are capable of inducing apoptosis independently of p53 in a number of systems, it seems likely that oncogenes lead to the activation of additional apoptotic pathways that could co-operate with p53 in the induction of apoptosis, in addition to modulating p53 target gene expression. In support of this notion is the identification of a number of genes that are induced by oncogenes that can activate apoptotic pathways.
p73 is a mediator of oncogene-induced apoptosis
Expression of oncogenes can induce the transcriptional activation of the p53 homologue p73, and this related protein can induce growth arrest and apoptosis, sharing many common target genes with p53 [19] . In contrast to oncogene-induced elevation of p53, the induction of p73 is ARF-independent, and, in the case of E2F1, occurs via direct transcriptional activation of the p73 gene. A role for p73 in oncogene-induced apoptosis has been demonstrated in cell lines using a dominant-negative p73 gene and by the use of compound p53/p73-null mouse cells [20, 21] .
If p73 is a critical mediator of oncogene-induced apoptosis, we might expect that, like p53, it would function as a tumour-suppressor gene. Although p73 is not frequently mutated in human tumours, methylation-dependent silencing has been reported in haematological malignancies. Further indirect evidence that inhibition of p73 can contribute to cancer development is provided by the strong bias for expression of p53 mutants that can also inhibit p73 function in human cancers [22] . A role for p73 in tumour development is complicated by the fact that the locus can generate mRNA from two different promoters and the products termed TAp73 and ⌬Np73. The ⌬Np73 isoforms lack the transactivation domain and, as such, cannot directly induce gene expression, growth arrest or apoptosis. The oligomerization domain of the ⌬Np73 is retained and this protein can function as a dominant negative regulator of TAp73 and p53, and is able to inhibit apoptosis induced by both TAp73 and p53. Interestingly, both TAp73 and p53 can induce ⌬Np73, thus forming a negative-feedback loop restricting p73 and p53 function. ⌬Np73 is thus a potential oncogene, and is over-expressed in a number of tumours, including neuroblastoma, where expression has been demonstrated to be a strong adverse prognostic marker [22] .
Is p73 the missing piece of the puzzle explaining how oncogenes induce apoptosis? It is clearly important in certain systems for the ability to trigger apoptosis: compound p53-/p73-null cells are extremely resistant to apoptosis in response to oncogene expression, and MEFs null for both p73 and the related p63 gene are extremely resistant to apoptosis, even though they retain wildtype p53 [21, 23] . Interestingly it seems that p53 is unable to induce activation of certain apoptotic target genes [Bax and PERP (p53-activated effector related to ] in the absence of its homologues, suggesting co-operation between these family members in the induction of apoptotic target genes [23] . However, as with p53, expression of p73 in MEFs in the absence of oncogenes leads to growth arrest rather than apoptosis. In addition, mutational analysis of E2F1 indicates that apoptosis can be induced by mutants unable to activate p73 [21, 24, 25] . It seems likely that p53 and p73 individually or in combination activate expression of apoptotic target genes that are necessary, but not sufficient for apoptosis in certain cell types. The oncogenes must trigger additional apoptotic pathways to co-operate with the p53/p73/p63 pathway to trigger apoptosis ( Figure 4) ; this of course begs the question, what are these genes?
Other mediators of oncogene-induced apoptosis
The increasing use of microarray technology is beginning to shed light on the genes activated by oncogenes. In contrast to previous approaches, the problem is too much information. For example, analysis of the effect of over-expressing E2F1 indicates that this results in modulation of the expression of between 1000 and 2000 genes [26] . These E2F-responsive genes encode proteins with diverse functions, potentially contributing to a number of biological programmes, including cell-cycle control, apoptosis, development and differentiation. E2F-responsive genes that may play a role in differentiation and development included members of critical signalling pathways, including the transforming growth factor ␤ superfamily [26] . In fact, even a number of genes encoding products that inhibit apoptosis are induced, including Bcl-2; what role these play in modulating E2F function is unclear. Do small inductions of many genes play a key role in mediating apoptosis or are there a more limited number of critical genes that modulate this process? The examples of ARF and p73 suggest that individual genes can play important roles, but of course this does not eliminate a role for multiple additional genes in the process.
Included in the group of genes that may enhance apoptosis are components of the basic apoptotic machinery itself, Apaf-1 (apoptotic protease-activating factor 1) and the caspases. Caspases are proteases that are key initiators and effectors of the process of apoptosis, cleaving multiple targets leading to the orderly breakup of the cell. In response to the release of cytochrome c Figure 4 . Mechanisms of oncogene-induced apoptosis Oncogenes can stimulate apoptosis via multiple downstream mediators. Several oncogenes have been demonstrated to stabilize the critical mediator of apoptosis p53, and this stabilization can occur by both ARF-dependent and ARF-independent mechanisms. In addition, oncogenes, including c-Myc and E2F1, can induce the expression of p73, which can play an important role in the induction of apoptosis. In addition to roles for p53 and p73, other target genes are induced that contribute the apoptosis, and it seems likely that a combination of a number of pro-apoptotic mediators co-operates to induce apoptosis in response to oncogenic signalling. Apoptosis from the mitochondria (an event triggered by a number of apoptotic insults), Apaf-1 processes the pro-caspase-9 to the active form, which then initiates a proleoytic caspase cascade by cleavage of other pro-caspases, leading to the induction of apoptosis. Expression of E1a or E2F1 resulted in significant increases in the levels of both Apaf-1 and several caspases [27, 28] . Elevation of components of the basic apoptotic effector machinery would sensitize cells to apoptosis, although signals to trigger activation of the machinery would still be necessary for the induction of apoptosis. The evidence suggests that these genes are direct E2F targets, providing compelling evidence of the intrinsic coupling of replicative and apoptotic pathways.
Oncogenes and cell-intrinsic and cell-extrinsic apoptotic pathways
There are two well-defined apoptotic pathways, termed the cell-extrinsic (death receptor) and the cell-intrinsic (mitochondrial), that can trigger apoptosis. The end point of both of these pathways is the activation of caspases and other molecules involved in mediating apoptosis. The cellextrinsic pathway triggers apoptosis by the recruitment and activation of the initiator caspase-8 to death receptors in response to ligand, activating the procaspase by proteolytic cleavage. This activated initiator caspase can set off a proteolytic cascade of caspase activation, triggering apoptosis. The cellintrinsic pathway induces apoptosis via the release of pro-apoptotic molecules from the mitochondria, including cytochrome c, which binds to Apaf-1 and caspase-9, triggering activation of caspase-9 and initiating activation of a caspase cleavage cascade.
Cell-intrinsic pathway
The important mediator of oncogene-induced apoptosis p53 is one of a number of signals that has been demonstrated to induce apoptosis by the cell-intrinsic pathway, promoting the release of pro-apoptotic molecules from the mitochondria. The p53 target genes Bax, Puma and Noxa encode important mediators of p53-induced apoptosis, and function as positive promoters of the cell-intrinsic pathway [7] . The most persuasive evidence for a role of the mitochondrial pathway in oncogene-induced apoptosis is that provided by analysis of cells from mice null for various components of the apoptotic machinery. Mice deficient in either Apaf-1 or caspase-9, but not caspase-8, showed a severely impaired apoptotic response to oncogenic signalling, suggesting that oncogenes trigger apoptosis via the cell-intrinsic pathway. These investigators extended their results with transformation assays, indicating that loss of Apaf-1 or caspase-9 could function, instead of loss of p53, and cooperate with proliferative oncogenes in tumour formation, suggesting that these genes could function as tumour suppressors [29] . This hypothesis is supported by analysis of melanomas, in which apaf-1 is often silenced by methylation [30] .
These data firmly establish a role for the cell-intrinsic pathways in mediating oncogene-induced apoptosis in certain cell types.
Cell-extrinsic pathway
A wealth of data also implicates a role for mitochondrion-independent pathways in apoptosis triggered by oncogenes. As already discussed, p53 is a critical mediator of oncogene-induced apoptosis, transcribing genes that function in the mitochondrial pathway. However, p53 also induces the expression of genes involved in death-receptor signalling, including the death receptors dr5 and fas; these receptors are capable of activating caspase in response to exposure to the appropriate ligand. In addition to inducing expression of genes involved in death-receptor signalling, p53 can also increase trafficking of these receptors to the cell surface [31] . Whether any of these targets would trigger apoptosis in a cell is likely to be dependent on a number of different signals, not least of which would be the presence of the deathreceptor ligand.
E1a, Myc and E2F can all sensitize cells to the presence of certain deathreceptor ligands, such as TNF␣ (tumour necrosis factor ␣), and in the case of c-Myc, death-receptor signalling has been shown to be necessary for apoptosis in certain cells [2] . One such ligand, TRAIL (TNF-related apoptotis-inducing ligand)/Apo2L shows a remarkable ability to induce apoptosis specifically in tumour cells, and is currently undergoing clinical trails as an anti-cancer agent. The molecular basis of this sensitivity of tumour compared with normal cells is unclear, but it does not seem to be determined by the presence of the receptors. Whatever the mechanism, it seems that the oncogenes can rewire cells to become sensitive to apoptosis in response to this ligand. In this light, it is interesting that both Myc and E2F1 have been shown to modulate the signalling from the TNF receptor. In addition to activating caspases, the TNF receptor can trigger additional signal-transduction pathways that inhibit apoptosis, including activation of the transcription factor nuclear factor B. Nuclear factor B is an important promoter of survival, inducing the expression of genes that inhibit apoptosis. Inhibition of nuclear factor B activity has been demonstrated to sensitize cells to apoptosis in response to multiple inducers of apoptosis. Expression of Myc and E2F1 can block activation of this anti-apoptotic signalling without interfering with the activation of caspase 8, rendering the cells sensitive to TNF␣ [32, 33] . The target genes of these transcription factors that are responsible for this phenotype remain to be identified.
There is also in vivo evidence that death receptors may play a role in oncogene-induced apoptosis. Generation of pRB-null embryos in a variety of genetic backgrounds has been informative in determining the mediators of apoptosis in response to deregulated E2F. Analysis of compound pRB-/Apaf-1-null embryos indicated that the apoptosis generated in certain tissues is not dependent on Apaf-1, eliminating an obligatory role for the cell-intrinsic pathway [34] . Of course, this does not prove that the apoptosis is the result of death-receptor signalling, but demonstrates that apoptosis generated by deregulation of E2F is mediated by distinct apoptotic pathways in a tissue-specific fashion.
If the death-receptor pathway is a critical mediator of oncogene-induced apoptosis, we would expect mutations that abrogate the activity of this pathway in human cancer. One such case appears to be neuroblastoma, in which mutation or loss of expression of caspase-8 appears to be extremely common in cases where there is amplification of N-Myc [35] . Since N-Myc can induce apoptosis, it may be that the loss of caspase-8 allows the tumour to tolerate the abnormally high levels of this pro-apoptotic oncogene.
Different oncogenes, same mechanisms?
A diverse array of proliferative oncogenes can trigger apoptosis, so are there common features, or a distinct series of mechanisms employed by different oncogenes? A definitive answer cannot yet be given, but certain features seem to be common to a number of oncogenes: several oncogenes have been demonstrated to induce apoptosis associated with a stabilization of p53, ARF can be induced by a number of different oncogenes, and p73 plays a role in apoptosis by several oncogenes.
What is interesting is that both ARF and p73 (and the caspases) are direct E2F target genes, suggesting that perhaps oncogenes could function via a stimulation of free E2F, driving both proliferation and apoptotic pathways [11, 20, 21, 27] . Despite E2F1 and E2F2 being capable of inducing entry into DNA synthesis, mice null for these transcription factors develop normally, but are tumour-prone [5] . This has led to the suggestion that certain E2Fs may function to detect aberrant or persistent proliferation and activate an apoptotic programme. Whether E2Fs play a role in mediating apoptosis in response to other oncogenes or whether there are distinct mechanisms remains to be determined.
Conclusions
Excessive mitotic signalling by activated oncogenes is coupled to apoptosis as a failsafe mechanism that prevents oncogenic transformation. For a fully malignant cell to emerge, this apoptosis must be overcome. This is reflected in the co-operation between genetic events that stimulate proliferation and those that inhibit apoptosis in the development of cancer.
This coupling of proliferative and apoptotic pathways provides a window of opportunity for cancer researchers. During the development of a tumour, compensating mutations, for example loss of p53 or ARF, may arise, giving protection against apoptosis stimulated by activation of oncogenes. Nevertheless, although tumour cells have to a certain extent escaped this apoptotic mechanism, some tumour cells still show enhanced sensitivity to apoptosis, a fact that may underlie the efficacy of many chemotherapeutic protocols. The challenge for investigators is to develop rational therapies to exploit the apoptotic pathways stimulated by oncogenic activation, or reactivate the apoptotic pathways that are lost during the development of tumours. A.C.P. is a Georgia Cancer Coalition Distinguished Scholar.
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